In Patients With Advanced Non-Small Cell Lung Cancer, BIM Deletion Decreases Survival

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the Journal of Thoracic Oncology, Asian patients with non-small cell lung cancer (NSCLC) and Bcl-2-like protein 11 (BIM) deletion who were treated with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy had a shorter progression-free survival (PFS) compared with those who did not have the deletion.

 

They also found that BIM deletion independently determines overall survival (OS) of patients with advanced NSCLC.

 

Researchers at the National Taiwan University Hospital in Taipei City, Taiwan, analyzed survival outcomes of 204 patients with advanced NSCLC with the BIM deletion who were treated with either chemotherapy or EGFR TKIs. They found that a median PFS of 4.6 months in patients with BIM deletion who were treated with EGFR TKIs compared with 8.6 months in those with wild type mutations (p=0.002).

 

In addition, the researchers observed a median PFS of 3.5 months in patients with BIM deletion who were treated with chemotherapy versus 5.6 months in wild type patients (p=0.016).

 

James Chih-Hsin Yang, MD, PhD, of the National Taiwan University Hospital suggests that future clinical studies should also stratify Asian NSCLC patients based on the BIM deletion polymorphism.

Mesothelioma: No Cure Yet, But Much Promise in New Therapies
BIM deletion in advanced NSCLC is associated with shorter progression free survival.
Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients.

Also, BIM deletion independently predicts overall survival (OS) of advanced NSCLC patients. The BIM protein can activate the programmed cell death also known as the apoptotic pathway in cells. BIM deletion has been detected in 12.8% of the Asian population but is very rarely observed in the Caucasian population.

All NSCLC patients treated with any therapy, targeted or chemotherapeutic, ultimately fail their therapy but at varying times.

READ FULL ARTICLE From Medical News Today

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs